

**UTILITY PATENT APPLICATION  
TRANSMITTAL**

Attorney Docket No. PU60075  
First Named Inventor Marquis

(For new nonprovisional applications under 37 CFR 1.53(b))

**"EXPRESS MAIL CERTIFICATE"**

"EXPRESS MAIL" MAILING LABEL NUMBER **EV332944398US** DATE OF DEPOSIT: **05 February 2004**

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:  
**COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.**

NAME OF PERSON MAILING PAPER OR FEE  
(TYPE OR PRINT) **Ben Ratliff**

SIGNATURE 

16334 U.S.P.T.O.  
0772817  
02564

**APPLICATION ELEMENTS**

*See MPEP chapter 600 concerning utility patent application contents.*

1.  The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. **19-2570**  
 General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))  
*(Submit an original, and a duplicate for fee processing)*

2.  The total fee is calculated as shown below:

Basic Filing fee	\$770.00
Total Claims 14 - 20 = 0 x \$18	\$ 0.00
Independent Claims 1 - 3 = 0 x \$86	\$ 0.00
<input type="checkbox"/> Multiple Dependent Claim present. \$290	
<b>TOTAL FILING FEE</b>	<b>\$770.00</b>

Cancel in this application original claims \_to\_ of the prior application before calculating the filing fee.

Charge **\$770.00** to the above indicated Deposit Account.

3a.  Specification excluding Drawings [Total Pages] **25**

3b.  Abstract on a separate sheet [Total Pages] **1**

4.  Drawing(s) (35 USC 113) [Total Sheets] \_\_\_\_\_

5.  Declaration and Power of Attorney [Total Pages] **3**

a.  Newly executed (original or copy)  
b.  Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 17a completed)*  
c.  Unsigned Declaration

*[Note Box 6 below]*

i.  **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6.  Incorporation By Reference *(useable if Box 5b is checked)*

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

7.  The Title of the Invention:  
**CATHEPSIN L INHIBITORS**

8.  Nucleotide and/or Amino Acid Sequence Submission  
a.  Computer Readable Copy  
b.  Paper Copy (identical to computer copy)  
c.  Statement verifying identity of above copies  
d.  Use the identical computer-readable form filed in Application No. \_\_\_\_\_, filed \_\_\_\_\_ as the computer-readable form for the instant application. (37 CFR 1.821(e))

**ACCOMPANYING APPLICATION PARTS**

9. a.  Information Disclosure Statement (IDS)  
b.  PTO-1449  
c.  Copies of all IDS Citations

10.  Assignment Papers (cover sheet & document(s))

11.  Prior Application is Assigned to:

*(for continuation/divisional with Box 17a completed)*

12.  Preliminary Amendment [Total Pages] **3**

13.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*

14.  Certified Copy of Priority Document(s)  
*(if foreign priority is claimed)*

15.  Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. \_\_\_\_\_ filed \_\_\_\_\_ A

PTO-1449 listing the references is enclosed.

16.  Other: \_\_\_\_\_

17.  Priority Information, check appropriate box and supply the requisite information

a. The accompanying application is a  Continuation  Divisional  Continuation-in-part (CIP) of prior application No: 0 filed 0.

b.  Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications:  
Application No. 60/447,558 filed 14 February 2003.

c. \*\* Add claim to priority via Preliminary Amendment.

Correspondence Address: GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Telephone (610) 270-5014 Fax (610) 270-5090

Signature  
Name

Registration  
No.

Respectfully Submitted,

James M. Kanagy

29,550

20462

PATENT TRADEMARK OFFICE